Exelixis (EXEL) sees Significant Insider Selling

Thursday, September 14, 2017 10:15 PM ET

Exelixis (EXEL) sees Significant Insider Selling

One Exelixis insider — Dr Lance Willsey, Director — today, sold 100,000 shares having a market value of approximately $2,688,000, as disclosed in a form 4 document filed with the SEC. This is the first insider buy/sell trade in the past 90 days.

The number of buy-sell trades for Exelixis is close to that of the 266 member peer company average. The Bio Therapeutic Drugs peer group saw 291 buy/sell trades during this period for an average of 1.1 transactions per company. However, the number of shares per buy/sell trade transacted by Exelixis insiders is higher. Within the peer group there were 7,588,255 shares purchased and 16,250,471 shares sold with company insiders disposing of 29,767 shares on average.

Significant insider buying and selling activity has been determined by eliminating all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers in data sourced in evaluating and writing this story.

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at info@uptickdata.com. Copyright 2017 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.